Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-LAMP Study of low-dose aspirin and mesalazine in Lynch syndrome
jRCTs031260615Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin and Salcrozine in hereditary nonpolyposis colorectal cancer (HNPCC) (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Cumulative incidence of colorectal tumors with and without aspirin over 2 years. Started Oct 2026; status: recruiting.
02
Drugs
aspirinSalcrozine
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)
Beyond the preview
Go deeper on jRCTs031260615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260615.